GW Pharmaceuticals said on Thursday that it has started the second of two Phase 3 trials of Epidiolex, which is used for the treatment of Lennox-Gastaut syndrome (LGS). In 2014, GW received orphan drug designation from the US Food and Drug Administration for Epidiolex for the treatment of LGS and it
Read moreLondon-based bio-pharmaceutical company GW Pharmaceuticals announced it will go cap in hand to investors in the US, although the exact terms of the share issue will depend on market conditions. On Tuesday, the company said its plans to sell 1.25m American Depositary Shares (ADSs) on the NASDAQ G
Read more